4,670 Shares in Haemonetics Corporation $HAE Bought by Cetera Trust Company N.A

Cetera Trust Company N.A bought a new stake in Haemonetics Corporation (NYSE:HAE) during the 2nd quarter, Holdings Channel reports. The fund bought 4,670 shares of the medical instruments supplier’s stock, valued at approximately $350,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kemnay Advisory Services Inc. bought a new stake in shares of Haemonetics in the 4th quarter valued at about $26,000. Leonteq Securities AG bought a new position in Haemonetics during the 4th quarter worth approximately $30,000. EverSource Wealth Advisors LLC grew its holdings in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. Kestra Advisory Services LLC acquired a new position in Haemonetics during the fourth quarter valued at approximately $34,000. Finally, Kelleher Financial Advisors bought a new stake in Haemonetics in the second quarter valued at approximately $38,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Down 0.4%

NYSE:HAE opened at $108.34 on Tuesday. The company has a market cap of $4.93 billion, a P/E ratio of 53.11, a price-to-earnings-growth ratio of 2.18 and a beta of 0.52. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $109.57. The business has a 50 day moving average price of $82.32 and a two-hundred day moving average price of $68.81. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. During the same period last year, the company earned $1.10 earnings per share. The firm’s revenue was up 5.5% compared to the same quarter last year. As a group, analysts expect that Haemonetics Corporation will post 5.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HAE has been the topic of several analyst reports. Citigroup increased their target price on shares of Haemonetics from $79.00 to $92.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Weiss Ratings upgraded shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Mizuho raised their price objective on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Barrington Research boosted their target price on Haemonetics from $95.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. Finally, Wall Street Zen raised shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $97.56.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.